Matinas BioPharma annual meeting results: directors elected, say-on-pay approved, auditor ratified

Matinas BioPharma Holdings, Inc.

All 7 director nominees elected with ~92% of votes cast for each; broker non-votes ~62.5M shares.
Advisory vote on executive compensation passed with 56.5M for, 6.9M against, 1.1M abstain.
Ratification of EisnerAmper as auditor for FY 2022 approved with 126.1M for, 0.5M against, 0.5M abstain.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Matinas BioPharma Holdings, Inc. shareholders approved Advisory vote on compensation of the Company's named executive officers at the 2022-11-14 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2022-11-14

Exact text from the filing

The tabulation of votes with respect to this proposal was as follows: For Against Abstain Broker Non-Votes 56,522,115 6,902,448 1,110,330 62,538,516

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Matinas BioPharma Holdings, Inc. shareholders approved Ratification of appointment of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending December 31, 2022 at the 2022-11-14 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2022-11-14

Exact text from the filing

The tabulation of votes with respect to this proposal was as follows: For Against Abstain Broker Non-Votes 126,116,312 468,604 488,493 - -

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Matinas BioPharma Holdings, Inc. shareholders approved Election of directors to serve on the board of directors until the annual meeting of shareholders to be held in 2023 at the 2022-11-14 meeting.

Proposal: director election
Outcome: passed
Meeting: 2022-11-14

Exact text from the filing

The tabulation of votes with respect to the election of such directors was as follows: AUTHORITY BROKER FOR WITHELD NON-VOTE Herbert Conrad 59,278,388 5,256,505 62,538,516 Kathryn Corzo 59,698,087 4,836,806 62,538,516 Jerome D. Jabbour 60,041,871 4,493,022 62,538,516 Eric Ende 59,832,977 4,701,916 62,538,516 Natasha Giordano 59,185,407 5,349,486 62,538,516 James Scibetta 60,052,024 4,482,869 62,538,516 Matthew Wikler 60,446,318 4,088,575 62,538,516

View on SEC.gov

46 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Matinas BioPharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-032264

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.